Full Press Release Details
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively
2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range represents growth in excess of 60% over 2022 revenues excluding revenues from COVID-19 testing
Conference Call and Webcast Today at 8:30 a.m. ET
BOULDER, CO, March 6, 2023 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.
It has been a productive year for Biodesix, and I am extremely proud of our team's performance. 2022 saw a significant increase in adoption of our core lung diagnostics business, growing test volume by 54% and revenue 57% year over year. In addition, we continued to produce compelling clinical utility data, expand reimbursement coverage including Medicare coverage of our Nodify CDT test and new private coverage policies for our Nodify XL2 test. said Scott Hutton, CEO of Biodesix. Our strong performance and positive momentum gives us continued confidence for 2023.
Fourth Quarter and Full Year 2022 Financial Results
-Total revenue of $9.6 million and $38.2 million for the fourth quarter and fiscal 2022, respectively, an increase of 33% and decrease of 30% over the respective prior year comparable periods;
oContinued growth in core lung diagnostic sales, offset by the expected year-over-year decline in COVID-19 revenue due to the decrease in testing across the year.
-Core lung diagnostic revenue of $8.2 million and $29.3 million for the fourth quarter and fiscal 2022, respectively, an increase of 51% and 57% over the respective prior year comparable periods;
oStrong year-over-year performance in core lung diagnostics primarily driven by the increased adoption of Nodify Lung nodule management tests and, the highest total tests delivered in Company history.
-COVID-19 testing revenue declined to an immaterial amount for the fourth quarter and $5.2 million for fiscal 2022, a decrease of 96% and 83% over the respective prior year comparable periods;
oCommensurate with prior guidance resulting from the increase in COVID-19 vaccination rates across the U.S. and the adoption and availability of at-home testing, including the expiration of our most significant testing contracts.
-Biopharma Services revenue of $1.4 million and $3.7 million for the fourth quarter and fiscal 2022, respectively, a decrease of 1% and 34% over the respective prior year comparable periods;
oClinical trial enrollment and shipping logistics continue to recover but are still impacting timelines for existing and new agreements;
oEntering 2023 with highest dollars under contract in Company history, including both prospective and retrospective studies.
-Gross margin was $6.3 million or 66% and $24.1 million or 63% for the fourth quarter and fiscal 2022, respectively, as a percentage of revenue compared to 65% and 44% in the comparable prior year periods, primarily driven by the mix shift of sales to higher-margin core lung diagnostics and away from lower-margin COVID-19 testing;
-Operating expenses (excluding direct costs and expenses) of $20.2 million and $74.6 million for the fourth quarter and fiscal 2022, an increase of 23% and 15% over the respective prior year comparable periods;
oIncrease in operating expenses is primarily from increased sales and marketing expense from the hiring of new sales reps, increased travel-related costs as access to physicians returned to pre-pandemic levels, and increases in other non-employee related costs all resulting from year-over-year growth in core lung diagnostic revenue;
oIncludes non-cash stock compensation expense of $2.1 million and $6.0 million during fourth quarter and fiscal 2022, respectively.
-Net loss of $20.3 million and $65.4 million for the fourth quarter and fiscal 2022, respectively, an increase of 53% and 52% over the respective prior year comparable periods;
oIncludes loss on debt extinguishment and modification of $4.0 million and $7.0 million in the fourth quarter and fiscal 2022, respectively;
oFiscal 2021 included gain on debt extinguishment and modification of $2.3 million.
-Cash and cash equivalents of $43.1 million as of December 31, 2022;
oRaised $65.7 million of net proceeds during the quarter through debt and equity offerings and utilized $23.9 million to extinguish outstanding debt.
2023 Financial Outlook
-The Company anticipates generating between $52 million to $55 million in total revenue in 2023;
oGuidance represents anticipated 36-44% growth over 2022 total revenue from Lung Diagnostic testing, Biopharmaceutical Services and COVID-19 testing;
oExcluding 2022 COVID-19 testing revenue, Guidance represents anticipated 58-67% growth.
Conference call and webcast information
Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
For a full list of Biodesix's press releases and webinars, please visit biodesix.com.
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung nodule risk assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment
decisions across all stages of lung cancer with results in an average of two to three business days, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words believe, may, will, estimate, continue, anticipate, intend, plan, expect, predict, potential, opportunity, goals, or should, and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent annual report on Form 10-K, filed March 6, 2023. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Condensed Balance Sheets (unaudited)
(in thousands, except share data)
| As of December 31, | ||||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 43,088 | $ | 32,712 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $118 and $158 | 5,065 | 3,656 | ||||||
| Other current assets | 5,181 | 7,245 | ||||||
| Total current assets | 53,334 | 43,613 | ||||||
| Non current assets | ||||||||
| Property and equipment, net | 5,848 | 4,179 | ||||||
| Intangible assets, net | 9,797 | 11,617 | ||||||
| Operating lease right-of-use assets | 2,973 | |||||||
| Goodwill | 15,031 | 15,031 | ||||||
| Other long-term assets | 5,923 | 1,657 | ||||||
| Total non current assets | 39,572 | 32,484 | ||||||
| Total assets | $ | 92,906 | $ | 76,097 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,685 | $ | 1,662 | ||||
| Accrued liabilities | 8,218 | 7,665 | ||||||
| Deferred revenue | 962 | 1,850 | ||||||
| Current portion of operating lease liabilities | 1,543 | |||||||
| Current portion of contingent consideration | 10,341 | 17,764 | ||||||
| Current portion of notes payable | 49 | 19 | ||||||
| Other current liabilities | 41 | |||||||
| Total current liabilities | 22,839 | 28,960 | ||||||
| Non current liabilities | ||||||||
| Long term notes payable, net of current portion | 25,004 | 9,993 | ||||||
| Long-term operating lease liabilities | 5,254 | |||||||
| Contingent consideration | 18,645 | 16,028 | ||||||
| Other long-term liabilities | 558 | 1,389 | ||||||
| Total non current liabilities | 49,461 | 27,410 | ||||||
| Total liabilities | 72,300 | 56,370 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2022 and 2021) issued and outstanding | ||||||||
| Common stock, $0.001 par value, 200,000,000 authorized; 77,614,358 (2022) and 30,789,649 (2021) shares issued and outstanding | 78 | 31 | ||||||
| Additional paid in capital | 387,948 | 321,669 | ||||||
| Accumulated deficit | (367,420 | ) | (301,973 | ) | ||||
| Total stockholders' equity | 20,606 | 19,727 | ||||||
| Total liabilities and stockholders' equity | $ | 92,906 | $ | 76,097 |
Condensed Statements of Operations (unaudited)
(in thousands, except per share data)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | ||||||||||||||||
| COVID-19 | $ | 16 | $ | 425 | $ | 5,240 | $ | 30,227 | ||||||||
| Lung diagnostic | 8,241 | 5,439 | 29,298 | 18,710 | ||||||||||||
| Diagnostic testing revenue | 8,257 | 5,864 | 34,538 | 48,937 | ||||||||||||
| Biopharma services | 1,351 | 1,359 | 3,674 | 5,569 | ||||||||||||
| Total revenues | 9,608 | 7,223 | 38,212 | 54,506 | ||||||||||||
| Direct costs and expenses | 3,306 | 2,493 | 14,154 | 30,518 | ||||||||||||
| Research and development | 3,565 | 2,852 | 13,102 | 12,789 | ||||||||||||
| Sales, marketing, general and administrative | 16,626 | 13,558 | 61,462 | 50,517 | ||||||||||||
| Change in fair value of contingent consideration | 1,622 | |||||||||||||||
| Impairment loss on intangible assets | 81 | |||||||||||||||
| Total operating expenses | 23,497 | 18,903 | 88,799 | 95,446 | ||||||||||||
| Loss from operations | (13,889 | ) | (11,680 | ) | (50,587 | ) | (40,940 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (2,550 | ) | (1,496 | ) | (8,072 | ) | (4,508 | ) | ||||||||
| (Loss) gain on debt extinguishments, net | (3,977 | ) | (97 | ) | (6,981 | ) | 2,298 | |||||||||
| Change in fair value of warrant liability | 84 | 84 | ||||||||||||||
| Other (expense) income, net | (5 | ) | (10 | ) | 109 | (9 | ) | |||||||||
| Total other expense | (6,448 | ) | (1,603 | ) | (14,860 | ) | (2,219 | ) | ||||||||
| Net loss | $ | (20,337 | ) | $ | (13,283 | ) | $ | (65,447 | ) | $ | (43,159 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.35 | ) | $ | (0.49 | ) | $ | (1.55 | ) | $ | (1.58 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 57,805 | 27,063 | 42,103 | 27,365 |